We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+29.18%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$11.1B
AUM Growth
+$971M
Cap. Flow
-$906M
Cap. Flow %
-8.14%
Top 10 Hldgs %
79.46%
Holding
34
New
2
Increased
12
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$120M
2
UTHR icon
United Therapeutics
UTHR
+$83.2M
3
DFTX
Definium Therapeutics
DFTX
+$54.1M
4
COAG
Hemab Therapeutics
COAG
+$53.1M
5
ARWR icon
Arrowhead Research
ARWR
+$48.4M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$492M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$454M
3
TERN
Terns Pharmaceuticals
TERN
+$300M
4
SLNO
Soleno Therapeutics
SLNO
+$77M
5
ALKS icon
Alkermes
ALKS
+$42.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$22.6B
$1.51B 13.52%
2,777,777
+147,777
+6% +$83.2M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.4B
$1.36B 12.24%
5,111,111
+48,611
+1% +$11.4M
KRYS icon
3
Krystal Biotech
KRYS
$10.6B
$1.07B 9.64%
2,888,888
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.6B
$984M 8.84%
1,833,333
+15,152
+0.8% +$7.76M
ARGX icon
5
argenx
ARGX
$66.2B
$928M 8.33%
1,000,000
– –
ARWR icon
6
Arrowhead Research
ARWR
$12.5B
$926M 8.31%
11,355,555
+655,556
+6% +$48.4M
KYMR icon
7
Kymera Therapeutics
KYMR
$10B
$857M 7.7%
7,474,747
– –
RVMD icon
8
Revolution Medicines
RVMD
$47.4B
$430M 3.86%
2,297,000
-47,444
-2% -$6.93M
CYTK icon
9
Cytokinetics
CYTK
$10.8B
$426M 3.82%
4,999,999
+1,666,666
+50% +$120M
CELC icon
10
Celcuity
CELC
$4.56B
$356M 3.19%
3,400,000
+25,000
+0.7% +$2.88M
GPCR icon
11
Structure Therapeutics
GPCR
$3.51B
$352M 3.16%
6,555,555
– –
XENE icon
12
Xenon Pharmaceuticals
XENE
$6B
$349M 3.13%
5,777,777
– –
DFTX
13
Definium Therapeutics
DFTX
$5.89B
$338M 3.04%
7,188,888
+2,188,888
+44% +$54.1M
QURE icon
14
uniQure
QURE
$3.44B
$310M 2.78%
6,727,777
+768,182
+13% +$20.1M
VERA icon
15
Vera Therapeutics
VERA
$2.49B
$246M 2.21%
5,723,888
-165,000
-3% -$6.15M
TSHA icon
16
Taysha Gene Therapies
TSHA
$1.94B
$163M 1.46%
23,888,888
+2,188,888
+10% +$13M
OCUL icon
17
Ocular Therapeutix
OCUL
$2.38B
$123M 1.11%
12,540,000
+225,000
+2% +$2.04M
DMRA
18
Damora Therapeutics
DMRA
$1.89B
$98.4M 0.88%
3,783,000
– –
COAG
19
Hemab Therapeutics
COAG
$2.31B
$70.7M 0.64%
+1,925,150
New +$53.1M
GHRS icon
20
GH Research
GHRS
$1.97B
$48.4M 0.43%
1,800,000
– –
VRDN icon
21
Viridian Therapeutics
VRDN
$2.71B
$45.9M 0.41%
2,500,000
+1,000,000
+67% +$16.1M
SEPN
22
Septerna Inc
SEPN
$1.89B
$44.8M 0.4%
1,337,500
– –
AVTX icon
23
Avalo Therapeutics
AVTX
$1.08B
$43.1M 0.39%
2,333,333
+923,333
+65% +$14.6M
FTH
24
Faeth Therapeutics
FTH
$872M
$36.1M 0.32%
+1,444,039
New +$33.4M
WHWK
25
Whitehawk Therapeutics
WHWK
$278M
$13.1M 0.12%
2,849,402
– –
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Avoro Capital Advisors held 34 positions worth $11.1B, up 9.6% from $10.2B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Avoro Capital Advisors withdrew a net $906M in Q2 2026, closing 8 positions and reducing 3 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $492M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Hemab Therapeutics worth $70.7M.

  • Avoro Capital Advisors's largest Q2 2026 buy was Hemab Therapeutics: 1,925,150 shares worth $70.7M.
  • Avoro Capital Advisors added most to Cytokinetics in Q2 2026, an estimated $120M increase.
  • Avoro Capital Advisors's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $6.93M.
  • Avoro Capital Advisors fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $492M.
  • Avoro Capital Advisors's ten largest holdings make up 79% of its $11.1B portfolio in Q2 2026.
  • Avoro Capital Advisors opened 2 new positions and closed 8 in Q2 2026.
  • Avoro Capital Advisors's portfolio value rose 9.6% quarter-over-quarter to $11.1B.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.